Alira Health Announces X-COR Therapeutics as New Alira Health Ventures Portfolio Company
Alira Health Welcomes X-COR into Alira Health Ventures as Portfolio Company
FRAMINGHAM, MASSACHUSETTS – November 4, 2019 – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, welcomes X-COR Therapeutics as a portfolio company for Alira Health Ventures. X-COR is a disruptive new technology that is transforming support for patients with respiratory failure using an ultra-low flow extracorporeal CO2 removal device that is revolutionizing care and simplifying treatment of chronic lung disease. Alira Health Ventures manages a wholly owned incubator of portfolio companies in breakthrough technology that advance healthcare and impact patient lives.
“X-COR Therapeutics is pushing to deliver a novel therapy for patients with chronic respiratory failure. We are very excited to work with Alira Health and the strong network they have created in medical device innovation as we translate our work from the preclinical to clinical stage,” said Jayon Wang, Chief Executive Officer of X-COR.
“We look forward to our partnership with X-COR,” said Gabriele Brambilla, Alira Health’s Chief Executive Officer. “They are changing the game for patients with respiratory failure and advancing the medical device field in the process. Our Alira Health Ventures incubator program will help them to make a strong transition into their clinical stages and be positioned well for future commercialization.”
Alira Health Ventures manages a wholly owned incubator of portfolio companies in breakthrough technology that advance healthcare and impact patient lives.
About X-COR Therapeutics:
X-COR Therapeutics is a Boston based medical device company creating the first commercially available CO2 removal device that uses ultra-low-blood flows for a cheaper, safer, and more accessible treatment for acute respiratory failure.
X-COR Therapeutics is creating the first commercially available extracorporeal CO2 removal device that uses ultra-low-blood flow to treat patients with hypercarbic respiratory failure. This condition, which causes accumulation of CO2 levels in the blood, can be triggered by many chronic diseases, such as COPD and cystic fibrosis, as well as acute trauma or exposure to toxins.
X-COR’s core technology is a patent-pending medical device that allows physicians to remove excess CO2 from patients who are in symptomatic lung failure and its accompanying control algorithm that is based on machine-learning techniques. The system is compatible with existing medical device infrastructure for ease of use and deployment.
To learn more about X-COR, visit http://xcortherapeutics.com/.